Bile salts: unlocking the potential as bio-surfactant for enhanced drug absorption
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Drug Transport and Resistance Mechanisms · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Debility S et al Jalinoos [Claudius Galen]–Galen of Pergamon
2. Macierzanka A, Torcello-Gómez A, Jungnickel C, Maldonado-Valderrama J (2019) Bile salts in digestion and transport of lipids. Adv Coll Interface Sci 274:10204510.1016/j.cis.2019.102045 ↗
3. Sankhyan A, Pawar PK (2013) Metformin loaded non-ionic surfactant vesicles: optimization of formulation, effect of process variables and characterization. DARU J Pharm Sci 21:1–810.1186/2008-2231-21-7 ↗
4. Kundu S, Kumar S, Bajaj A (2015) Cross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implications. IUBMB Life 67(7):514–52310.1002/iub.1399 ↗
5. Ahmed M (2022) Functional, diagnostic and therapeutic aspects of bile. Clin Exp Gastroenterol 105–12010.2147/CEG.S360563 ↗
6. Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72(1):137–17410.1146/annurev.biochem.72.121801.161712 ↗
7. Fini A, Feroci G, Roda A (2002) Acidity in bile acid systems. Polyhedron 21(14–15):1421–142710.1016/S0277-5387(02)00968-3 ↗
8. Chang C-M, Bodmeier R (1997) Effect of dissolution media and additives on the drug release from cubic phase delivery systems. J Control Release 46(3):215–22210.1016/S0168-3659(96)01596-9 ↗
9. Moghimipour E, Ameri A, Handali S (2015) Absorption-enhancing effects of bile salts. Molecules 20(8):14451–1447310.3390/molecules200814451 ↗
10. Quinn M et al (2014) Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis 46(6):527–53410.1016/j.dld.2014.01.159 ↗
11. Stojančević M, Pavlović N, Goločorbin-Kon S, Mikov M (2013) Application of bile acids in drug formulation and delivery. Front Life Sci 7(3–4):112–12210.1080/21553769.2013.879925 ↗
12. Arora G et al (2011) Formulation and evaluation of controlled release matrix mucoadhesive tablets of domperidone using Salvia plebeian gum. J Adv Pharm Technol Res 2(3):163–16910.4103/2231-4040.85534 ↗
13. Pavlović N et al (2018) Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol 9:128310.3389/fphar.2018.01283 ↗
14. Shaikh M, Derle ND, Bhamber R (2012) Permeability enhancement techniques for poorly permeable drugs: a review. J Appl Pharm Sci 2(7):34–39
15. Aburahma MH (2016) Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv 23(6):1847–1867
16. Thakur G, Singh A, Singh I (2016) Chitosan-montmorillonite polymer composites: formulation and evaluation of sustained release tablets of aceclofenac. Sci Pharm 84(4):603–61810.3390/scipharm84040603 ↗
17. Small DM (1968) Size and structure of bile salt micelles: influence of structure, concentration, counterion concentration, pH, and temperature, ACS Publications10.1021/ba-1968-0084.ch004 ↗
18. Poša M, Pilipović A (2017) Self-association of C3 and C6 epimers of hyodeoxycholate anions in aqueous medium: hydrophobicity, critical micelle concentration and aggregation number. J Mol Liq 238:48–5710.1016/j.molliq.2017.04.109 ↗
19. Naso JN, Bellesi FA, Ruiz-Henestrosa VMP, Pilosof AM (2019) Studies on the interactions between bile salts and food emulsifiers under in vitro duodenal digestion conditions to evaluate their bile salt binding potential. Colloids Surf, B 174:493–50010.1016/j.colsurfb.2018.11.024 ↗
20. Swaan PW, Szoka FC Jr, Øie S (1996) Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv Drug Deliv Rev 20(1):59–8210.1016/0169-409X(95)00130-Y ↗
21. Azum N, Rub MA, Asiri AM (2019) Bile salt–bile salt interaction in mixed monolayer and mixed micelle formation. J Chem Thermodyn 128:406–41410.1016/j.jct.2018.08.030 ↗
22. Malik NA (2016) Solubilization and interaction studies of bile salts with surfactants and drugs: a review. Appl Biochem Biotechnol 179:179–20110.1007/s12010-016-1987-x ↗
23. Gibaldi M, Feldman S (1970) Mechanisms of surfactant effects on drug absorption. J Pharm Sci 59(5):579–58910.1002/jps.2600590502 ↗
24. Hofmann A, Small DM (1967) Detergent properties of bile salts: correlation with physiological function. Annu Rev Med 18(1):333–37610.1146/annurev.me.18.020167.002001 ↗
25. Coreta-Gomes FM et al (2012) Quantification of cholesterol solubilized in bile salt micellar aqueous solutions using 13C nuclear magnetic resonance. Anal Biochem 427(1):41–4810.1016/j.ab.2012.04.028 ↗
26. Mrestani Y, Bretschneider B, Härtl A, Neubert RH (2003) In-vitro and in-vivo studies of cefpirom using bile salts as absorption enhancers. J Pharm Pharmacol 55(12):1601–160610.1211/0022357022214 ↗
27. Mudgil M et al (2012) Nanotechnology: a new approach for ocular drug delivery system. Int J Pharm Pharm Sci 4(2):105–12
28. Reis S et al (2004) Noninvasive methods to determine the critical micelle concentration of some bile acid salts. Anal Biochem 334(1):117–12610.1016/j.ab.2004.07.017 ↗
29. Roda A, Hofmann AF, Mysels KJ (1983) The influence of bile salt structure on self-association in aqueous solutions. J Biol Chem 258(10):6362–637010.1016/S0021-9258(18)32418-9 ↗
30. Mooranian A et al (2020) Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Sci Rep 10(1):10610.1038/s41598-019-53999-1 ↗
31. Ahmad J et al (2017) Bile salt stabilized vesicles (bilosomes): a novel nano-pharmaceutical design for oral delivery of proteins and peptides. Curr Pharm Des 23(11):1575–158810.2174/1381612823666170124111142 ↗
32. Holm R, Müllertz A, Mu H (2013) Bile salts and their importance for drug absorption. Int J Pharm 453(1):44–5510.1016/j.ijpharm.2013.04.003 ↗
33. Parekh PY, Patel VI, Khimani MR and Bahadur P (2023) Self-assembly of bile salts and their mixed aggregates as building blocks for smart aggregates. Adv Colloid Interface Sci 10284610.1016/j.cis.2023.102846 ↗
34. Albalak A et al (1996) Effects of submicellar bile salt concentrations on biological membrane permeability to low molecular weight non-ionic solutes. Biochemistry 35(24):7936–794510.1021/bi960497i ↗
35. Attili A et al (1986) Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 19(1):57–6910.1016/0306-9877(86)90137-4 ↗
36. Van Hasselt P et al (2009) The influence of bile acids on the oral bioavailability of vitamin K encapsulated in polymeric micelles. J Control Release 133(2):161–16810.1016/j.jconrel.2008.09.089 ↗
37. Van Hasselt P (2009). Vitamin K prophylaxis revisited: focus on risk factors, University Utrecht
38. Kabedev A et al (2021) Molecular dynamics simulations reveal membrane interactions for poorly water-soluble drugs: impact of bile solubilization and drug aggregation. J Pharm Sci 110(1):176–18510.1016/j.xphs.2020.10.061 ↗
39. Alrefai WA, Gill RK (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24:1803–182310.1007/s11095-007-9289-1 ↗
40. Deng F, Bae YH (2020) Bile acid transporter-mediated oral drug delivery. J Control Release 327:100–11610.1016/j.jconrel.2020.07.034 ↗
41. Bashyal S, Seo J-E, Choi YW, Lee S (2021) Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach. J Control Release 338:644–66110.1016/j.jconrel.2021.08.060 ↗
42. Kweon S et al (2023) Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery. Biomater Res 27(1):1–1810.1186/s40824-023-00421-7 ↗
43. Murakami T, Bodor E, Bodor N (2021) Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs. Expert Opin Drug Metab Toxicol 17(5):555–58010.1080/17425255.2021.1902986 ↗
44. Zhang B et al (2016) Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel. Die Pharmazie-An Int J Pharma Sci 71(6):320–326
45. Rupp C, Steckel H, Müller BW (2010) Mixed micelle formation with phosphatidylcholines: the influence of surfactants with different molecule structures. Int J Pharm 387(1–2):120–12810.1016/j.ijpharm.2009.12.018 ↗
46. Guo Q et al (2016) Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability. Drug Des, Dev Therapy 3789–379810.2147/DDDT.S119918 ↗
47. Yu X et al (2015) Ginsenoside Rg3 bile salt-phosphatidylcholine-based mixed micelles: design, characterization, and evaluation. Chem Pharm Bull 63(5):361–36810.1248/cpb.c15-00045 ↗
48. Hammad MA, Müller BW (1999) Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine–mixed micelles. Drug Dev Ind Pharm 25(4):409–41710.1081/DDC-100102190 ↗
49. Cautela J et al (2017) Wormlike reverse micelles in lecithin/bile salt/water mixtures in oil. Colloids Surf, A 532:411–41910.1016/j.colsurfa.2017.04.052 ↗
50. Fornasier M et al (2021) Tuning lipid structure by bile salts: hexosomes for topical administration of catechin. Colloids Surf, B 199:11156410.1016/j.colsurfb.2021.111564 ↗
51. Dening TJ, Douglas JT, Hageman MJ (2021) Do macrocyclic peptide drugs interact with bile salts under simulated gastrointestinal conditions? Mol Pharm 18(8):3086–309810.1021/acs.molpharmaceut.1c00309 ↗
52. Matheson AB et al (2017) The development of phytosterol-lecithin mixed micelles and organogels. Food Funct 8(12):4547–455410.1039/C7FO01271C ↗
53. Jain S, Reddy CSK, Swami R, Kushwah V (2018) Amphotericin B loaded chitosan nanoparticles: implication of bile salt stabilization on gastrointestinal stability, permeability and oral bioavailability. AAPS PharmSciTech 19:3152–316410.1208/s12249-018-1153-6 ↗
54. Liu X, Clifford A, Zhao Q, Zhitomirsky I (2020) Biomimetic strategies in colloidal-electrochemical deposition of functional materials and composites using chenodeoxycholic acid. Colloids Surf, A 603:12518910.1016/j.colsurfa.2020.125189 ↗
55. Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H (2016) The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artif Cells Nanomedicine Biotechnol 44(6):1508–151910.3109/21691401.2015.1058807 ↗
56. Mooranian A et al (2021) Chenodeoxycholic acid pharmacology in biotechnology and transplantable pharmaceutical applications for tissue delivery: an acute preclinical study. Cells 10(9):243710.3390/cells10092437 ↗
57. Qian M et al (2022) Discovery of novel cholic acid derivatives as highly potent agonists for G protein-coupled bile acid receptor. Bioorg Chem 120:10558810.1016/j.bioorg.2021.105588 ↗
58. Salminen S et al (1998) Functional food science and gastrointestinal physiology and function. Br J Nutr 80(S1):S147–S17110.1079/BJN19980108 ↗
59. Chan OH, Stewart BH (1996) Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today 1(11):461–47310.1016/1359-6446(96)10039-8 ↗
60. Jeon OC et al (2013) Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharm Res 30(4):959–96710.1007/s11095-012-0932-0 ↗
61. Lillienau J, Schteingart CD, Hofmann AF (1992) Physicochemical and physiological properties of cholylsarcosine. A potential replacement detergent for bile acid deficiency states in the small intestine. J Clin Invest 89(2):420–43110.1172/JCI115601 ↗
62. Michael S et al (2000) Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur J Pharm Sci 10(2):133–14010.1016/S0928-0987(99)00093-7 ↗
63. Yang L, Zhang H, Mikov M, Tucker IG (2009) Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Mol Pharm 6(2):448–45610.1021/mp800143w ↗
64. Chen G et al (2012) Effect of ketocholate derivatives on methotrexate uptake in Caco-2 cell monolayers. Int J Pharm 433(1–2):89–9310.1016/j.ijpharm.2012.04.077 ↗
65. Chen G, Fawcett JP, Mikov M, Tucker IG (2009) Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. J Pharm Pharmacol 61(7):953–95910.1211/jpp.61.07.0016 ↗
66. Leuenberger M et al (2021) Characterization of novel fluorescent bile salt derivatives for studying human bile salt and organic anion transporters. J Pharmacol Exp Ther 377(3):346–35710.1124/jpet.120.000449 ↗
67. Schneider S et al (1991) Fluorescent derivatives of bile salts. I. Synthesis and properties of NBD-amino derivatives of bile salts. J Lipid Res 32(11):1755–176710.1016/S0022-2275(20)41630-X ↗
68. Schramm U et al (1991) Fluorescent derivatives of bile salts. II. Suitability of NBD-amino derivatives of bile salts for the study of biological transport. J Lipid Res 32(11):1769–177910.1016/S0022-2275(20)41631-1 ↗
69. Lalić-Popović M et al (2013) Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabetes Res10.1155/2013/598603 ↗
70. Greenwood J et al (1991) The effect of bile salts on the permeability and ultrastructure of the perfused, energy-depleted, rat blood-brain barrier. J Cereb Blood Flow Metab 11(4):644–65410.1038/jcbfm.1991.116 ↗
71. Watanabe A, Fujiwara M, Tominaga S, Nagashima H (1987) Bile acid and ammonia-induced brain edema in rats. Hiroshima J Med Sci 36(2):257–259
72. Jain S et al (2019) Mechanistic insights into high permeation vesicle-mediated synergistic enhancement of transdermal drug permeation. Nanomedicine 14(16):2227–224110.2217/nnm-2018-0519 ↗
73. Khafagy E-S, Almutairy BK, Abu Lila AS (2023) Tailoring of novel bile salt stabilized vesicles for enhanced transdermal delivery of simvastatin: a new therapeutic approach against inflammation. Polymers 15(3):67710.3390/polym15030677 ↗
74. Lohan S et al (2021) QbD-steered development of mixed nanomicelles of galantamine: Demonstration of enhanced brain uptake, prolonged systemic retention and improved biopharmaceutical attributes. Int J Pharm 600:12048210.1016/j.ijpharm.2021.120482 ↗
75. Fetih G, Ibrahim M, Amin M (2011) Design and characterization of transdermal films containing ketorolac tromethamine. Int J PharmTech Res 3(1):449–458
76. Alvarez-Figueroa MJ, Muggli-Galaz C, González PM (2019) Effect of the aggregation state of bile salts on their transdermal absorption enhancing properties. J Drug Deliv Sci Technol 54:10133310.1016/j.jddst.2019.101333 ↗
77. Salem HF et al (2022) Evaluation of metformin hydrochloride tailoring bilosomes as an effective transdermal nanocarrier. Int J Nanomedicine 1185–120110.2147/IJN.S345505 ↗
78. Ahmed S, Kassem MA and Sayed S (2020) Bilosomes as promising nanovesicular carriers for improved transdermal delivery: construction, in vitro optimization, ex vivo permeation and in vivo evaluation. Int J Nanomedicine 9783–979810.2147/IJN.S278688 ↗
79. Sasaki H et al (1995) Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. J Drug Target 3(2):129–13510.3109/10611869509059212 ↗
80. Hayakawa E et al (1992) Conjunctival penetration of insulin and peptide drugs in the albino rabbit. Pharm Res 9(6):769–77510.1023/A:1015803605621 ↗
81. Dai Y et al (2013) Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine 8:1921–1933
82. Dalpiaz A et al (2019) Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. Eur J Pharm Biopharm 144:91–10010.1016/j.ejpb.2019.09.008 ↗
83. Johansson F et al (2002) Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci 17(1–2):63–7110.1016/S0928-0987(02)00133-1 ↗
84. Miyake M et al (2021) Spermine with sodium taurocholate enhances pulmonary absorption of macromolecules in rats. J Pharm Sci 110(10):3464–347010.1016/j.xphs.2021.06.015 ↗
85. Natalini PM et al (2019) The influence of surfactant on the properties of albendazole-bile salts particles designed for lung delivery. J Drug Deliv Sci Technol 53:10116210.1016/j.jddst.2019.101162 ↗
86. Pilcer G, Amighi K (2010) Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392(1–2):1–1910.1016/j.ijpharm.2010.03.017 ↗
87. Sørli JB et al (2018) Bile salt enhancers for inhalation: correlation between in vitro and in vivo lung effects. Int J Pharm 550(1–2):114–12210.1016/j.ijpharm.2018.08.031 ↗
88. Yamamoto A et al (1992) A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit. J Pharmacol Exp Ther 263(1):25–31
89. Dolai J, Mandal K, Jana NR (2021) Nanoparticle size effects in biomedical applications. ACS Appl Nano Mater 4(7):6471–649610.1021/acsanm.1c00987 ↗
90. Heiligtag FJ, Niederberger M (2013) The fascinating world of nanoparticle research. Mater Today 16(7–8):262–27110.1016/j.mattod.2013.07.004 ↗
91. Khan I, Saeed K, Khan I (2019) Nanoparticles: properties, applications and toxicities. Arab J Chem 12(7):908–93110.1016/j.arabjc.2017.05.011 ↗
92. Miyajima K, Yokoi M, Komatsu H, Nakagaki M (1986) Interaction of β-cyclodextrin with bile salts in aqueous solutions. Chem Pharm Bull 34(3):1395–139810.1248/cpb.34.1395 ↗
93. Olesen NE, Westh P, Holm R (2016) Displacement of drugs from cyclodextrin complexes by bile salts: a suggestion of an intestinal drug-solubilizing capacity from an in vitro model. J Pharm Sci 105(9):2640–264710.1002/jps.24678 ↗
94. Camilleri M (2022) Bile acid detergency:permeability, inflammation, and effects of sulfation. Am J Physiol-Gastrointest Liver Physiol 322(5):480–48810.1152/ajpgi.00011.2022 ↗
95. Zhao D, Hirst BH (1990) Bile salt-induced increases in duodenal brush-border membrane proton permeability, fluidity, and fragility. Dig Dis Sci 35:589–59510.1007/BF01540406 ↗
96. Wu S et al (2019) A delivery system for oral administration of proteins/peptides through bile acid transport channels. J Pharm Sci 108(6):2143–215210.1016/j.xphs.2019.01.027 ↗
97. Yang G et al (2019) Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides. Int J Nanomedicine 14:2267–228010.2147/IJN.S194934 ↗
98. Kim KS, Suzuki K, Cho H, Bae YH (2020) Selected factors affecting oral bioavailability of nanoparticles surface-conjugated with glycocholic acid via intestinal lymphatic pathway. Mol Pharm 17(11):4346–435310.1021/acs.molpharmaceut.0c00764 ↗
99. Singh I, Swami R, Khan W, Sistla R (2014) Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin Drug Deliv 11(2):211–22910.1517/17425247.2014.866088 ↗
100. Mutlu-Agardan NB, Han S (2021) In vitro and in vivo evaluations on nanoparticle and phospholipid hybrid nanoparticles with absorption enhancers for oral insulin delivery. Pharm Dev Technol 26(2):157–16610.1080/10837450.2020.1849282 ↗